ONPOSMA Trademark

Trademark Overview

On Thursday, October 23, 2025, a trademark application was filed for ONPOSMA with the United States Patent and Trademark Office. The USPTO has given the ONPOSMA trademark a serial number of 79442197. The federal status of this trademark filing is NON-FINAL ACTION COUNTED - NOT MAILED as of Thursday, March 12, 2026. This trademark is owned by Cellbion Co., Ltd.. The ONPOSMA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations; radiopharmaceuticals; radioactive materials for medical purposes; sealed radioactive substances for medical purposes; radioactive elements for medical use; radiological contrast substances for medical purposes; radiopharmaceutical preparations for diagnostic purposes; radioisotope markers for therapeutic or diagnostic use; radiopharmaceuticals for treatment of prostate cancer; radiopharmaceuticals for cancer treatment; radioactive pharmaceuticals; radioactive therapeutic pharmaceuticals; pharmaceutical preparations for treatment of metastatic cancer; nuclear medicine therapeutic preparations; pharmaceutical preparations for cancer treatment; contrast agents for nuclear medicine imaging and therapy; prostate cancer-targeting agents; peptide-based radiolabeled agents for therapeutic or diagnostic use.
onposma

General Information

Serial Number79442197
Word MarkONPOSMA
Filing DateThursday, October 23, 2025
Status640 - NON-FINAL ACTION COUNTED - NOT MAILED
Status DateThursday, March 12, 2026
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesPharmaceutical preparations; radiopharmaceuticals; radioactive materials for medical purposes; sealed radioactive substances for medical purposes; radioactive elements for medical use; radiological contrast substances for medical purposes; radiopharmaceutical preparations for diagnostic purposes; radioisotope markers for therapeutic or diagnostic use; radiopharmaceuticals for treatment of prostate cancer; radiopharmaceuticals for cancer treatment; radioactive pharmaceuticals; radioactive therapeutic pharmaceuticals; pharmaceutical preparations for treatment of metastatic cancer; nuclear medicine therapeutic preparations; pharmaceutical preparations for cancer treatment; contrast agents for nuclear medicine imaging and therapy; prostate cancer-targeting agents; peptide-based radiolabeled agents for therapeutic or diagnostic use.
Translation of Words in MarkThe wording ONPOSMA has no meaning in a foreign language.

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, January 29, 2026
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameCellbion Co., Ltd.
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressKR

Trademark Events

Event DateEvent Description
Thursday, January 29, 2026SN ASSIGNED FOR SECT 66A APPL FROM IB
Sunday, February 1, 2026NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sunday, February 1, 2026APPLICATION FILING RECEIPT MAILED
Tuesday, March 10, 2026ASSIGNED TO EXAMINER
Thursday, March 12, 2026NON-FINAL ACTION WRITTEN
Friday, March 13, 2026NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Friday, March 13, 2026NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Friday, March 13, 2026NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW

Related Keywords

onposma radioactive cancer preparations treatment therapeutic purposes medical agents pharmaceutical diagnostic